EUVIMEDEUVIMED entdecken
Leserbrief

Defining clinically meaningful benefit in mild-to-moderate hidradenitis suppurativa trials

Rahib K Islam, Lacey M Falgout, Nicholas J Culotta, Christopher J Sayed, Christopher J Haas

Journal of the American Academy of Dermatology · 2026-08

DOI: 10.1016/j.jaad.2026.06.153 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Journal of the American Academy of Dermatology, 2026-08. Verfasst von Rahib K Islam und 4 weiteren Autor:innen. Beteiligte Einrichtung: Louisiana State University Health Sciences Center, School of Medicine, New Orleans, Louisiana; Department of Dermatology, Louisiana State University …. Die Arbeit nennt 5 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

Hurley stageabscessdermatologydermatology life quality indexhidradenitis suppurativarandomized clinical trialsruxolitinib

Autor:innen und Institutionen

  • Louisiana State University Health Sciences Center, School of Medicine, New Orleans, Louisiana; Department of Dermatology, Louisiana State University Health Sciences Center, New Orleans, Louisiana.
  • Department of Dermatology, Tulane University School of Medicine, New Orleans, Louisiana.
  • Department of Dermatology, Louisiana State University Health Sciences Center, New Orleans, Louisiana.
  • Department of Dermatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
  • Department of Dermatology, Louisiana State University Health Sciences Center, New Orleans, Louisiana. Electronic address: chaas2@lsuhsc.edu.

Zitieren

APA

Islam, R. K., Falgout, L. M., Culotta, N. J., Sayed, C. J., & Haas, C. J. (2026). Defining clinically meaningful benefit in mild-to-moderate hidradenitis suppurativa trials. Journal of the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2026.06.153

Vancouver

Islam RK, Falgout LM, Culotta NJ, Sayed CJ, Haas CJ. Defining clinically meaningful benefit in mild-to-moderate hidradenitis suppurativa trials. Journal of the American Academy of Dermatology. 2026. doi:10.1016/j.jaad.2026.06.153

BibTeX
@article{Islam2026,
  author = {Islam, Rahib K and Falgout, Lacey M and Culotta, Nicholas J and Sayed, Christopher J and Haas, Christopher J},
  title = {Defining clinically meaningful benefit in mild-to-moderate hidradenitis suppurativa trials},
  journal = {Journal of the American Academy of Dermatology},
  year = {2026},
  doi = {10.1016/j.jaad.2026.06.153}
}
Kostenlos starten →